Assembly Bio Shares Jump as Gilead Licenses Herpes Program; Cash Runway Reaches 2028

Gilead Licensing Validates Antiviral Pipeline

The primary driver of investor optimism was the announcement that Gilead Sciences has exercised its option to license Assembly Bio’s helicase-primase inhibitor (HPI) program. This includes candidates ABI-5366 and ABI-1179, which are being developed for recurrent genital herpes. The move follows positive Phase 1b interim data and resulted in a net $35 million option fee for Assembly Bio.

CEO Jason Okazaki characterized 2025 as a "pivotal year," noting that the early decision by Gilead validates the company's long-acting oral antiviral strategy. By mid-2026, Assembly Bio will decide whether to opt into a 40% U.S. cost-profit share for the program, a move that could transition the company from a royalty-receiver to a more active commercial partner. This decision will be contingent on the development plan and budget provided by Gilead.

Financial Fortification and Revenue Growth

Assembly Bio’s financial profile saw a dramatic shift in 2025. Total revenue reached $72.3 million, a 153% increase from the $28.5 million reported in 2024. This growth was almost entirely attributed to increased collaboration funding from the Gilead partnership.

The company’s net loss attributable to common stockholders narrowed to $6.1 million, or $0.55 per share, compared to a loss of $40.2 million ($6.69 per share) in the prior year. This improvement reflects the influx of collaboration capital which offset a rise in research and development (R&D) expenses. R&D costs climbed to $64.8 million as clinical trials for the HPI program accelerated, while general and administrative expenses rose slightly to $19.6 million due to professional fees and stock-based compensation.

Crucially for biotech investors, the company ended the year with $248.1 million in cash, cash equivalents, and marketable securities. Management now projects this capital will fund operations into 2028, a significant extension from previous guidance that provides a multi-year cushion to reach key clinical milestones without the immediate need for dilutive financing.

Pipeline Momentum and Future Catalysts

While the Gilead partnership remains the centerpiece, Assembly Bio is also advancing its solo pipeline. The company regained sole rights to ABI-4334, a highly potent capsid assembly modulator candidate for chronic hepatitis B virus (HBV), after Gilead declined its option. Assembly has already initiated a structured process to find a new partner for this program to continue its clinical development.

Looking ahead, the company expects to initiate a Phase 2 clinical study for ABI-6250, an oral entry inhibitor for chronic hepatitis delta virus (HDV), by the end of 2026. In the near term, investors are looking toward the ESCMID Congress in April 2026 and the EASL Congress in May 2026, where additional data for the herpes and HDV programs will be presented.

Market Reaction

Shares of ASMB responded favorably to the de-risking news, climbing $0.94 to $28.45 in extended trading. The 3.42% gain reflects market approval of the extended cash runway and the formal commitment from Gilead, which provides a clear regulatory and commercial path for the company's most advanced candidates. The stock had previously closed the regular session at $27.51.